Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Atypical hemolytic uremic syndrome with MCP mutations preceded by respiratory infection.

Yasuda K, Sasaki K, Yamato M, Rakugi H, Isaka Y, Hayashi T, Piras R, Bresin E.

CEN Case Rep. 2013 May;2(1):34-37. doi: 10.1007/s13730-012-0034-1. Epub 2012 Oct 5.

2.

Complement-mediated thrombotic microangiopathy secondary to sepsis-induced disseminated intravascular coagulation successfully treated with eculizumab: A case report.

Abe T, Sasaki A, Ueda T, Miyakawa Y, Ochiai H.

Medicine (Baltimore). 2017 Feb;96(6):e6056. doi: 10.1097/MD.0000000000006056.

3.

Atypical hemolytic uremic syndrome in first trimester pregnancy successfully treated with eculizumab.

Andries G, Karass M, Yandrapalli S, Linder K, Liu D, Nelson J, Pawar R, Chugh S.

Exp Hematol Oncol. 2017 Jan 13;6:4. doi: 10.1186/s40164-017-0064-7. eCollection 2017.

4.

Complement related kidney diseases: Recurrence after transplantation.

Salvadori M, Bertoni E.

World J Transplant. 2016 Dec 24;6(4):632-645. doi: 10.5500/wjt.v6.i4.632. Review.

5.

Adjustment of Eculizumab Dosage Pattern in Patients with Atypical Hemolytic Uremic Syndrome with Suboptimal Response to Standard Treatment Pattern.

García Monteavaro C, Peralta Roselló C, Quiroga B, Baltar Martín JM, Castillo Eraso L, de Álvaro Moreno F, Martínez Vea A, Visus-Fernández de Manzanos MT.

Case Rep Nephrol. 2016;2016:7471082. doi: 10.1155/2016/7471082. Epub 2016 Nov 29.

6.

Eculizumab refractory thrombotic thrombocytopenic purpura secondary to post-endoscopic retrograde cholangiopancreatography pancreatitis in a patient.

Malik F, Ali N, Ahsan I, Ghani AR, Fidler C.

J Community Hosp Intern Med Perspect. 2016 Dec 15;6(6):32310. doi: 10.3402/jchimp.v6.32310. eCollection 2016.

7.

A Case Report and Literature Review of Eculizumab Withdrawal in Atypical Hemolytic-Uremic Syndrome.

Quiroga B, de Lorenzo A, Vega C, de Alvaro F.

Am J Case Rep. 2016 Dec 15;17:950-956. Review.

8.

The complement system in age-related macular degeneration: A review of rare genetic variants and implications for personalized treatment.

Geerlings MJ, de Jong EK, den Hollander AI.

Mol Immunol. 2017 Apr;84:65-76. doi: 10.1016/j.molimm.2016.11.016. Epub 2016 Dec 6.

9.

Thrombotic microangiopathies: a general approach to diagnosis and management.

Arnold DM, Patriquin CJ, Nazy I.

CMAJ. 2017 Jan 30;189(4):E153-E159. doi: 10.1503/cmaj.160142. Epub 2016 Oct 17. Review. No abstract available.

PMID:
27754896
10.

Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome.

Westra D, Volokhina EB, van der Molen RG, van der Velden TJ, Jeronimus-Klaasen A, Goertz J, Gracchi V, Dorresteijn EM, Bouts AH, Keijzer-Veen MG, van Wijk JA, Bakker JA, Roos A, van den Heuvel LP, van de Kar NC.

Pediatr Nephrol. 2017 Feb;32(2):297-309. doi: 10.1007/s00467-016-3496-0. Epub 2016 Oct 7.

11.

Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature.

Kavanagh D, McGlasson S, Jury A, Williams J, Scolding N, Bellamy C, Gunther C, Ritchie D, Gale DP, Kanwar YS, Challis R, Buist H, Overell J, Weller B, Flossmann O, Blunden M, Meyer EP, Krucker T, Evans SJ, Campbell IL, Jackson AP, Chandran S, Hunt DP.

Blood. 2016 Dec 15;128(24):2824-2833. Epub 2016 Sep 23.

12.

The Genetics of Ultra-Rare Renal Disease.

Muff-Luett M, Nester CM.

J Pediatr Genet. 2016 Mar;5(1):33-42. doi: 10.1055/s-0036-1572515. Epub 2016 Feb 23. Review.

13.

A Rare Recurrent 4q25 Proximal Deletion Not Involving the PITX2 Gene: A Genomic Disorder Distinct from Axenfeld-Rieger Syndrome.

Heithaus JL, Twyman KA, Batanian JR.

Mol Syndromol. 2016 Jul;7(3):138-43. doi: 10.1159/000447077. Epub 2016 Jun 23.

14.

Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea.

Cheong HI, Jo SK, Yoon SS, Cho H, Kim JS, Kim YO, Koo JR, Park Y, Park YS, Shin JI, Yoo KH, Oh D.

J Korean Med Sci. 2016 Oct;31(10):1516-28. doi: 10.3346/jkms.2016.31.10.1516.

15.

Maintenance eculizumab dose adjustment in the treatment of atypical hemolytic uremic syndrome: a case report and review of the literature.

Thomson N, Ulrickson M.

Clin Case Rep. 2016 Jul 6;4(8):773-6. doi: 10.1002/ccr3.628. eCollection 2016 Aug.

16.

Atypical Hemolytic Uremic Syndrome Recurrence after Renal Transplantation: C3-Glomerulonephritis as an Initial Presentation.

Bouatou Y, Bacchi VF, Villard J, Moll S, Martin PY, Hadaya K.

Transplant Direct. 2015 Mar 26;1(2):e9. doi: 10.1097/TXD.0000000000000518. eCollection 2015 Mar.

17.

Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN.

Salvadori M, Rosso G.

World J Nephrol. 2016 Jul 6;5(4):308-20. doi: 10.5527/wjn.v5.i4.308. Review.

18.

Complete remission of thrombotic microangiopathy after treatment with eculizumab in a patient with non-Shiga toxin-associated bacterial enteritis: A case report.

Omura T, Watanabe E, Otsuka Y, Yoshida Y, Kato H, Nangaku M, Miyata T, Oda S.

Medicine (Baltimore). 2016 Jul;95(27):e4104. doi: 10.1097/MD.0000000000004104.

19.

Critical appraisal of eculizumab for atypical hemolytic uremic syndrome.

Palma LM, Langman CB.

J Blood Med. 2016 Apr 12;7:39-72. doi: 10.2147/JBM.S36249. eCollection 2016. Review.

20.

Regulators of complement activity mediate inhibitory mechanisms through a common C3b-binding mode.

Forneris F, Wu J, Xue X, Ricklin D, Lin Z, Sfyroera G, Tzekou A, Volokhina E, Granneman JC, Hauhart R, Bertram P, Liszewski MK, Atkinson JP, Lambris JD, Gros P.

EMBO J. 2016 May 17;35(10):1133-49. doi: 10.15252/embj.201593673. Epub 2016 Mar 24.

Supplemental Content

Support Center